EGFR and neoplasm: The patient was treated with Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as well as definitive local therapy for primary and metastatic sites, resulting in significant tumor reduction.